U.S. Markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.03 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.08 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    84.83
    -0.72 (-0.84%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     
  • BTC-USD

    34,450.28
    -3,906.07 (-10.18%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Moderna's Flagship Venture Firm Cashed $1.4B From Stock Sale In Two Months: Forbes

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MRNA
  • Almost a decade ago, Flagship Pioneering, a VC fund run and majority-owned by Moderna Inc’s (NASDAQ: MRNA) chairman and co-founder, Noubar Afeyan, poured cash into the company, even when Moderna had faced some early setbacks.

  • Over the last 13 months, since the World Health Organization declared a pandemic, Flagship has sold off Moderna shares worth more than $1.4 billion, as reported by Forbes.

  • The most recent sales came in late February and March this year when two Flagship funds, Fund IV and Fund IV-RX, sold off 53% of their stake in the company.

  • Noubar Afeyan put the sales into motion days after the company’s COVID-19 vaccine was authorized by the FDA in December last year.

  • The funds also sold 1 million shares for $68.2 million (pretax) in May 2020.

  • According to SEC filings, Afeyan owns at least 75% of Flagship, and the firm directly owns 4% of Flagship Ventures Fund IV but doesn’t own any of Flagship Ventures Fund IV-Rx.

  • Moderna’s CEO Stéphane Bancel sold around 1.7 million shares, about 7% of his stake for $161.2 million since March 2020. He still owns a 6% stake in the company, part of an estimated $5.5 billion net worth that includes about $1.5 billion in Moderna options.

  • The next biggest seller was Moderna’s chief medical officer, Tal Zaks, who made $108.2 million from the sale of the shares.

  • On the other hand, the founding investor, Timothy Springer, and co-founder Robert Langer have benefited from the stupendous share price growth. Still, neither has sold a share since the company was founded in 2010.

  • Price Action: MRNA shares are down 0.6% at $168.44 in market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.